Skip to main content
GemVax & KAEL Co.,Ltd. logo

GemVax & KAEL Co.,Ltd. — Investor Relations & Filings

Ticker · 082270 ISIN · KR7082270000 KO Manufacturing
Open in API
Filings indexed 650 across all filing types
Latest filing 2023-01-06 Major Shareholding Noti…
Country KR South Korea
Listing KO 082270

About GemVax & KAEL Co.,Ltd.

https://gemvax.com/

GemVax & KAEL is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics. Its lead drug candidate is GV1001, a synthetic peptide composed of 16 amino acids, which has demonstrated multiple actions including the modulation of neuroinflammation and reduction of oxidative stress. The company's development pipeline primarily targets neurodegenerative diseases, such as Alzheimer's disease and Progressive Supranuclear Palsy (PSP). Other therapeutic areas under investigation include pancreatic cancer and benign prostatic hyperplasia. GemVax & KAEL is actively advancing its programs through clinical trials to evaluate the efficacy and safety of its novel treatments.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership, including major shareholding notifications, changes in special relationships, and pledge agreements. This fits the definition of a Major Shareholding Notification (MRQ).
2023-01-06 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a short announcement (under 1,000 characters) notifying investors about an upcoming Investor Relations (IR) event (기업설명회). It provides the date, location, and purpose of the meeting, and mentions that materials will be distributed at the event or posted on the exchange website. Since it is an announcement of an event rather than the presentation slides themselves, and it serves as a regulatory notification of corporate activity, it fits best as a Regulatory Filing (RNS).
2023-01-03 Korean
투자판단관련주요경영사항(진행성 핵상마비 치료제로서 GV1001의 국내 2a상 임상시험계획(IND) 신청)
Regulatory Filings Classification · 100% confidence The document is a regulatory disclosure from GemVax regarding the filing of an Investigational New Drug (IND) application for a Phase 2a clinical trial. It is a specific corporate announcement regarding business operations and regulatory compliance, which does not fit into categories like financial reports, dividends, or shareholder meetings. As it is a formal regulatory disclosure of a material event, it falls under the 'Regulatory Filings' category.
2022-12-29 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date for the purpose of determining shareholders eligible to vote at an upcoming Annual General Meeting (AGM). It does not contain the full report or proxy materials themselves, but rather serves as a formal notice of a corporate action related to shareholder rights. Given the nature of the announcement and its brevity, it falls under the category of general regulatory filings.
2022-12-16 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in ownership, and pledge agreements of major shareholders (Gem & Company and related parties) in GemVax & Kael. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2022-12-16 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership, special relationships, and collateral agreements for the company GemVax & Kael. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema, as it tracks significant ownership thresholds and changes in control.
2022-12-02 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.